Prostate Biopsy Specimen Analysis
Customize your policy alerts
Sign up for Presbyterian Health Plan Policy AHS-G2007 alerts
Get alerted when Policy AHS-G2007 changes without checking for updates manually.
Monitor payer policy activity
Coverage for pathological examination of prostate biopsy tissue used to diagnose, stage, or manage suspected prostate cancer, including biopsies following abnormal PSA results, suspicious examination or imaging findings, or persistent suspicion after a negative biopsy.
The policy was reviewed and updated with revisions to the background, guidelines and recommendations, and evidence-based scientific references.
The policy clarified that each vial, regardless of the number of enclosed biopsy cores, is considered a single specimen for billing purposes.
The policy previously added a New Mexico Medicaid link to the applicable state and federal regulations section.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.